Form D · Pharmaceuticals
Vesuvius Pharmaceuticals, Inc.
Boston, MA · CIK 0001629592
Offering snapshot reported Jan 5, 2015 · SEC filing
- Reported sold
- $10.2M Offering amount: $33M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 22, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 5, 2015 | Initial | $10,225,258 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-231374
Source: Form D, filed Jan 5, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Cordo | Executive |
| Luke Evnin | Director |
| Phil Gutry | Director |
| Daniel Hicklin | Director, Executive |
| Arnold Oronsky | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
C/O Mpm Capital 200 Clarendon St., 54 Th Floor
Boston, MA, 02116
Boston, MA, 02116